Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03891654
Other study ID # 18-2874.cc
Secondary ID P30CA046934
Status Completed
Phase Early Phase 1
First received
Last updated
Start date August 1, 2019
Est. completion date April 28, 2022

Study information

Verified date April 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study that uses a standard of care technique, Stereotactic Body Radiation Therapy (SBRT), in combination with Dynamic Contrast Enhanced Computed Tomography (DCE-CT) to determine if perfusion changes from SBRT of liver cancer may be used for outcome assessment and prediction of prognosis.


Description:

Patients will undergo standard of care SBRT while also receiving DCE-CT, also known as perfusion CT, pre-treatment, 6 hours post-treatment and 6 weeks post-treatment.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date April 28, 2022
Est. primary completion date December 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Provision to sign and date the consent form 2. Stated willingness to comply with all study procedures and be available for the duration of the study 3. Be a Male or Female aged 18-100 4. Diagnosed with Liver HCC or metastases 5. Must be receiving or will plan to receive SBRT for Liver HCC or metastases Exclusion Criteria: 1. Allergy to iodine contrast 2. CT with contrast not offered as a Standard of Care 3. Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Dynamic Contrast Enhanced Computed Tomography
Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.

Locations

Country Name City State
United States University of Colorado Denver Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary DCE-CT Perfusion Metrics: K-Trans Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through K-Trans (extraction-flow product) as shown through DCE-CT imaging. Baseline to end of follow-up, up to 12 weeks
Primary DCE-CT Perfusion Metrics: Blood Volume Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through blood volume as shown through DCE-CT imaging. Baseline to end of follow-up, up to 12 weeks
Primary DCE-CT Perfusion Metrics: Blood Flow Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through blood flow as shown through DCE-CT imaging. Baseline to end of follow-up, up to 12 weeks
Secondary Correlation Between Patient Demographics and K-Trans: Age Stratify K-Trans results by age to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and K-Trans: Sex Stratify K-Trans results by sex to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and K-Trans: Race Stratify K-Trans results by race to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and K-Trans: Clinical Stage of Disease Stratify K-Trans results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Volume: Age Stratify blood volume results age to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Volume: Sex Stratify blood volume results sex to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Volume: Race Stratify blood volume results race to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Volume: Clinical Stage of Disease Stratify blood volume results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Flow: Age Stratify blood flow results age to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Flow: Sex Stratify blood flow results sex to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Flow: Race Stratify blood flow results race to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
Secondary Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease Stratify blood flow results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics Post follow-up to end of study, up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2